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INTRODUCTION
Lung cancer accounts the most lethal malignancy worldwide, with high rates of metastatic disease at presentation [1] . Most common metastatic locations are lungs, lymph nodes, liver, brain and bones, whilst other metastatic sites, like muscles, are rare and more often found during disease evolution [2] . Here we describe a clinical case of a patient diagnosed of a muscular metastases on left forearm as first clinical sign of a lung adenocarcinoma.
CASE PRESENTATION
An 83-year-old former smoker male consulted his primary care physician because of pain in the distal third of his left forearm, which was accompanied with a slow-growing painful tumor. He also referred having paresthesias on fourth and fifth left fingers which had appeared few days ago (Figure 1a ). Doppler ultrasonography and magnetic resonance imaging were performed to obtain a complete evaluation. They revealed a 35×26×46 mm mass with cystic necrotic areas and large soft-tissue edema on the flexor digitorum superficialis muscle (Figure 1b,c) . Core needle biopsy was performed, and a pathological examination revealed a striated muscle tissue infiltrated by the adenocarcinoma (CK7-and TTF-1 positive). Further imaging with a thoracoabdominal-pelvic CT scan was performed based on the pathological findings. As a result of the CT scan, two lung spiculated lesions were found: one in the right lower lobe and the other in the apical segment of the right upper lobe (Figure 1d ,e). The patient was diagnosed with stage IV lung adenocarcinoma (cT4NxM1b) [3] .
Given the continuous pain in his upper right extremity, he was offered palliative local radiation therapy on his forearm metastases. The patient had a great performance status (Karfnosky: 90%, no significant comorbidities); therefore, he was offered a chemotherapy regimen with carboplatin plus pemetrexed, which he started receiving with good tolerance. Magnetic resonance imaging demonstrated a good radiological response with persistence of a residual non-vascularized lesion that was 7×10 mm in size.
Written informed consent was obtained from the patient who participated in this case. 
DISCUSSION
The most frequent extrathoracic locations for lung cancer metastases are the liver, adrenal glands, brain, bone, and kidneys. Skeletal muscle (SM) metastases are uncommon (prevalence close to 0-0.8%). There are three theories that attempt to explain the low affinity of cancer cells to skeletal tissues: mechanical (muscle contractions could prevent the tumor to settle due to high blood pressure and variable local blood flow), metabolic (as a consequence of elevated lactate production, pH instability, and variable oxygen tension), and immunologic hypothesis (role of cellular and humoral immunity) [4] [5] [6] .
The clinical presentation in 80% of cases is a painful palpable mass (mean size of 6 cm) that is usually located in the back, chest wall, abdomen, or thigh muscles. Magnetic resonance imaging and fluorine-18-fluorodeoxyglucose positron emission tomography are the most commonly used imaging tests to differentiate muscle metastases from other lesions with similar presentations (primary sarcomas and lymphomas). Establishing the definitive diagnosis necessitates to perform a biopsy [4] .
Therapeutic options include observation, radiotherapy (useful for pain control and reduction in lesion size), chemotherapy, and surgery (for isolated lesions after a long disease-free interval). The expected survival rate fluctuates between less than 9 months to 3 years after the diagnosis of the mass. To conclude, treatment depends on the localization, clinical presentation, and prognosis of the primary tumor [4, 5] .
To our knowledge, this is the first published case of SM metastases in the flexor digitorum superficialis muscle as the first manifestation in lung cancer. 
